Cite
HARVARD Citation
Reckamp, K. et al. (2022). Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L. Current medical research and opinion. pp. 1587-1593. [Online].